Edition:
United States

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

7.15USD
15 Dec 2017
Change (% chg)

$-0.15 (-2.05%)
Prev Close
$7.30
Open
$7.25
Day's High
$7.47
Day's Low
$7.10
Volume
1,069,532
Avg. Vol
120,861
52-wk High
$10.50
52-wk Low
$5.35

Latest Key Developments (Source: Significant Developments)

Corbus Pharmaceuticals Q3 loss per share $0.14
Wednesday, 8 Nov 2017 08:05am EST 

Nov 8 (Reuters) - Corbus Pharmaceuticals Holdings Inc : :Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.14.Corbus Pharmaceuticals Holdings Inc - ‍company expects current cash on hand to fund operations into Q4 of 2019,based on current planned expenditures​.Corbus Pharmaceuticals Holdings Inc - qtrly revenue $796,312 versus $742,558.  Full Article

Corbus Pharma reports improvement in skin conditions in a mid-stage study
Monday, 6 Nov 2017 08:30am EST 

Nov 6 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study.Corbus Pharmaceuticals Holdings Inc - ‍Company on track to commence phase 3 study Q4 2017​.Corbus Pharmaceuticals Holdings Inc - Were no severe or serious adverse events and no clinically significant laboratory abnormalities related to drug​.Corbus Pharmaceuticals - "‍Our focus now is to ensure successful execution of our phase 3 study, and we are on track to commence this before year end"​.  Full Article

Corbus Pharma prices underwritten public offering of common stock
Tuesday, 24 Oct 2017 09:06am EDT 

Oct 24 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals Holdings, Inc. prices underwritten public offering of common stock.Says public offering of 4.65 million common shares priced at $7.00 per share.  Full Article

Corbus Pharmaceuticals Holdings announces proposed public offering of common stock
Monday, 23 Oct 2017 04:01pm EDT 

Oct 24 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals Holdings Inc announces proposed public offering of common stock.Corbus Pharmaceuticals Holdings Inc - ‍Corbus intends to use proceeds of proposed offering to fund its continued development of anabasum, among others​.  Full Article

Corbus Pharma's inflammatory disease drug succeeds mid-stage study
Thursday, 19 Oct 2017 07:30am EDT 

Oct 19 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports positive topline results from phase 2 study in rare autoimmune disease dermatomyositis.Corbus Pharmaceuticals Holdings Inc - ‍Anabasum was well tolerated with no severe or serious side effects associated with drug​.Corbus Pharmaceuticals Holdings Inc - ‍Anabasum also outperformed placebo in multiple secondary efficacy outcomes studied​.  Full Article

Corbus Pharmaceuticals Holdings reports Q2 loss per share $0.15
Wednesday, 9 Aug 2017 07:05am EDT 

Aug 9 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports 2017 second quarter financial results and provides business update.Q2 loss per share $0.15.Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Corbus Pharmaceuticals Holdings Inc - ‍ended Q2 with approximately $43.0 million of cash and cash equivalents​.  Full Article

Corbus Pharmaceuticals Q1 loss per share $0.16
Tuesday, 9 May 2017 09:00am EDT 

May 9 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::Corbus Pharmaceuticals reports 2017 first quarter financial results and provides business update.Q1 loss per share $0.16.Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Company ended quarter with $49 million of cash which is sufficient to fund operations through end of 2018.  Full Article

Corbus Pharma outlines U.S. approval path for anabasum
Wednesday, 5 Apr 2017 08:30am EDT 

Corbus Pharmaceuticals Holdings Inc : Corbus Pharmaceuticals to commence single Phase 3 study of anabasum for treatment of systemic sclerosis after guidance from end-of-phase 2 meeting with FDA . Expects to enroll its first patient in single phase 3 study in fourth quarter of 2017 . Engaging EMA for discussing clinical development of anabasum to support application for marketing approval to treat systemic sclerosis .Plans to complete enrollment of 52-week Phase 3 international study in 2018 with results expected in 2019, NDA application thereafter.  Full Article

Corbus Pharma says cystic fibrosis study data to be reported by Q1 2017 end
Thursday, 9 Mar 2017 07:00am EST 

Corbus Pharmaceuticals Holdings Inc : Corbus Pharmaceuticals reports 2016 financial results and provides 2017 business update . Topline data for phase 2 cystic fibrosis study expected to be reported by end of Q1 2017 .Company has sufficient capital to fund its operations into Q4 2018.  Full Article

Corbus Pharma reports positive topline results from phase 2 study of Resunab
Monday, 14 Nov 2016 06:30am EST 

Corbus Pharmaceuticals Holdings Inc : Corbus Pharma says positive topline results showing clear signal of clinical benefit with Resunab (JBT-101) in phase 2 study in Systemic Sclerosis . there were no serious, severe, or unexpected adverse events related to JBT-101 .difference in CRISS scores over trial period between JBT-101 and placebo groups was significant.  Full Article

BRIEF-Corbus Pharmaceuticals Q3 loss per share $0.14

* Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements